Defining and characterizing neuronal senescence, 'neurescence', as G arrested cells.

Trends Neurosci

Department of Translational Neuroscience, Wake Forest University School of Medicine, Winston-Salem, NC, USA; Department of Internal Medicine Section on Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA; Salisbury VA Medical Center, Salisbury, NC, USA. Electronic address:

Published: December 2024

AI Article Synopsis

  • - Cellular senescence is a state where cells resist dying and stop dividing, first seen in dividing cells but now recognized in non-dividing cells like neurons.
  • - Confusion arises in understanding senescence in neurons because they can be in a quiescent (inactive) state, leading researchers to suggest a new term, 'neurescent,' for these senescent neurons.
  • - The study proposes criteria to identify neurescent cells, explains their differences from quiescent neurons, and contrasts neurescent states with traditional senescence observed in dividing cells.

Article Abstract

Cellular senescence is a cell state characterized by resistance to apoptosis and stable cell cycle arrest. Senescence was first observed in mitotic cells in vitro. Recent evidence from in vivo studies and human tissue indicates that postmitotic cells, including neurons, may also become senescent. The quiescent cell state of neurons and inconsistent descriptions of neuronal senescence across studies, however, have caused confusion in this burgeoning field. We summarize evidence demonstrating that exit from G quiescence may protect neurons against apoptosis and predispose them toward senescence. Additionally, we propose the term 'neurescent' for senescent neurons and introduce the cell state, G, to describe cell cycle arrest achieved by passing through G quiescence. Criteria are provided to identify neurescent cells, distinguish them from G quiescent neurons, and compare neurescent phenotypes with classic replicative senescence.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tins.2024.09.006DOI Listing

Publication Analysis

Top Keywords

cell state
12
neuronal senescence
8
cell cycle
8
cycle arrest
8
senescence
6
cell
5
neurons
5
defining characterizing
4
characterizing neuronal
4
senescence 'neurescence'
4

Similar Publications

Since decades after temozolomide was approved, no effective drugs have been developed. Undoubtedly, blood-brain barrier (BBB) penetration is a severe issue that should be overcome in glioblastoma multiforme (GBM) drug development. In this research, we were inspired by linezolid through structural modification with several bioactive moieties to achieve the desired brain delivery.

View Article and Find Full Text PDF

Background: Age-related macular degeneration (AMD), a condition of multifactorial origin, is a major cause of irreversible vision loss in industrialized countries. The dry late stage of the disease, known as geographic atrophy (GA), is characterized by progressive loss of photoreceptor cells and retinal pigment epithelial cells in the central retina. An estimated 300 000 to 550 000 people in Germany suffer from GA.

View Article and Find Full Text PDF

Breast cancers of the IntClust-2 type, characterized by amplification of a small portion of chromosome 11, have a median survival of only five years. Several cancer-relevant genes occupy this portion of chromosome 11, and it is thought that overexpression of a combination of driver genes in this region is responsible for the poor outcome of women in this group. In this study we used a gene editing method to knock out, one by one, each of 198 genes that are located within the amplified region of chromosome 11 and determined how much each of these genes contributed to the survival of breast cancer cells.

View Article and Find Full Text PDF

Purpose: Orvacabtagene autoleucel (orva-cel; JCARH125), a CAR T-cell therapy targeting B-cell maturation antigen (BCMA), was evaluated in relapsed/refractory multiple myeloma (RRMM) patients in the EVOLVE phase 1/2 study (NCT03430011). We applied a modified piecewise model to characterize orva-cel transgene kinetics and assessed the impact of various covariates on its pharmacokinetics (PK).

Experimental Design: The population PK analysis included 159 patients from the EVOLVE study.

View Article and Find Full Text PDF

Purpose: Therapeutic efficacy of KRASG12C(OFF) inhibitors (KRASG12Ci) in KRASG12C-mutant non-small cell lung cancer (NSCLC) varies widely. The activation status of RAS signaling in tumors with KRASG12C mutation remains unclear, as its ability to cycle between the active GTP-bound and inactive GDP-bound states may influence downstream pathway activation and therapeutic responses. We hypothesized that the interaction between RAS and its downstream effector RAF in tumors may serve as indicators of RAS activity, rendering NSCLC tumors with a high degree of RAS engagement and downstream effects more responsive to KRASG12Ci compared to tumors with lower RAS---RAF interaction.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!